Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort.
biological therapy
drug prescription
drug safety
gender bias
psoriasis
sex
sex bias
gender
Journal
Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310
Informations de publication
Date de publication:
04 01 2021
04 01 2021
Historique:
pubmed:
4
12
2020
medline:
24
6
2021
entrez:
3
12
2020
Statut:
epublish
Résumé
The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients with psoriasis (58.3% males), followed from January 2008 to November 2018, to determine whether sex influences prescription, effectiveness of therapy, and the risk of adverse events. The results show that women are more likely than men to be prescribed biologics. There were no differences between men and women in effectiveness of therapy, measured in terms of drug survival. Women were more likely to develop adverse events, but the difference in risk was small and does not justify different management. Study limitations include residual confounding and the use of drug survival as a proxy for effectiveness.
Identifiants
pubmed: 33269405
doi: 10.2340/00015555-3711
pmc: PMC9309850
doi:
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
adv00354Références
J Invest Dermatol. 2017 Feb;137(2):313-321
pubmed: 27677836
Am J Clin Dermatol. 2017 Aug;18(4):583-590
pubmed: 28342016
Stat Med. 1998 Oct 15;17(19):2265-81
pubmed: 9802183
J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1913-1920
pubmed: 31177583
J Dtsch Dermatol Ges. 2017 Mar;15(3):309-317
pubmed: 28240404
Br J Dermatol. 2016 Aug;175(2):340-7
pubmed: 26989852
J Eur Acad Dermatol Venereol. 2019 Oct;33(10):e362-e364
pubmed: 31063605
JAMA Dermatol. 2018 Nov 1;154(11):1251-1253
pubmed: 30267061
Am J Epidemiol. 2013 Feb 15;177(4):292-8
pubmed: 23371353
EMBO Rep. 2012 Jun 29;13(7):596-603
pubmed: 22699937
J Eur Acad Dermatol Venereol. 2019 Apr;33(4):700-708
pubmed: 30388318
Int J Dermatol. 2014 Nov;53(11):e507-11
pubmed: 25266080
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Health Res Policy Syst. 2017 Feb 15;15(1):11
pubmed: 28202078
Stat Med. 2017 Nov 30;36(27):4391-4400
pubmed: 28913837
Actas Dermosifiliogr. 2017 Jan - Feb;108(1):3-5
pubmed: 27765164
J Eur Acad Dermatol Venereol. 2017 Feb;31(2):205-212
pubmed: 27573025
J Dermatolog Treat. 2017 Nov;28(7):635-641
pubmed: 28789582
BMC Womens Health. 2015 Oct 26;15:94
pubmed: 26503700
BMC Med. 2012 Aug 01;10:82
pubmed: 22853635
Br J Dermatol. 2019 Sep;181(3):450-458
pubmed: 30729500
J Am Acad Dermatol. 2019 Jan;80(1):251-265.e19
pubmed: 29928910
Acta Derm Venereol. 2017 Jan 4;97(1):91-97
pubmed: 27304233
PLoS One. 2013 May 15;8(5):e63619
pubmed: 23691076
J Invest Dermatol. 2015 Nov;135(11):2632-2640
pubmed: 26053050
Syst Rev. 2014 Apr 10;3:33
pubmed: 24720875
J Eur Acad Dermatol Venereol. 2013 Feb;27(2):220-6
pubmed: 22329829
Stat Med. 1991 Apr;10(4):585-98
pubmed: 2057657
Actas Dermosifiliogr. 2011 Mar;102(2):132-41
pubmed: 21377137
Br J Dermatol. 2019 May;180(5):1069-1076
pubmed: 30155885
Qual Life Res. 2016 Nov;25(11):2739-2754
pubmed: 27259580